Indian Antivirals Supplier & Wholesale Distributor.

Antiretroviral therapy (ART) procurement under the Global Fund and PEPFAR is the single largest pooled HIV-medicine market in the world, and Indian generic manufacturers have held more than 80% of the WHO-prequalified ART supply for over a decade. Tenofovir / lamivudine / dolutegravir (TLD) is now the WHO-recommended first-line regimen for adults; TAF-based regimens are second-line. Paediatric formulations (abacavir-lamivudine + dolutegravir-10mg, raltegravir granules) are smaller-volume but harder to source. Our antivirals catalogue carries the full first-line and second-line ART list against WHO PQ status, with the dossier ready for Global Fund Pooled Procurement Mechanism (PPM), national HIV programme tenders (Nigeria's NACA, Kenya's NASCOP, South Africa's national ART tender) and PEPFAR direct buying.

Hepatitis C direct-acting antivirals (sofosbuvir, sofosbuvir-velpatasvir, sofosbuvir-daclatasvir, glecaprevir-pibrentasvir) transformed the disease from chronic to curable in 8–12 weeks. Indian generic versions under the original Gilead and AbbVie voluntary licensing arrangements made the per-treatment cost workable for low- and middle-income countries — exactly the price point hospital pharmacy buyers in Egypt's national HCV elimination programme, the Pakistan Punjab HCV programme, and the Africa CDC HCV co-infection lane all needed. We carry the dossier pack for both donor-funded and direct-buyer windows.

Outside HIV and HCV, the antivirals catalogue carries the influenza neuraminidase inhibitors (oseltamivir, zanamivir), CMV antivirals (ganciclovir, valganciclovir) for transplant procurement, and the COVID-era residual (remdesivir, molnupiravir, nirmatrelvir-ritonavir) where national stockpile re-orders are still active. Compliance routes vary — WHO PQ where the molecule is on the list, NAFDAC / PPB / SAHPRA registration for African direct-buy markets, MHRA Specials for UK shortage management on niche antivirals.